Philipson - Trump's Rx: Reducing Drug Prices, Saving Innovation ...

Experts say the bipartisan Break Up Big Medicine Act — aimed at breaking up vertically integrated healthcare companies — faces slim chances of passing despite recent PBM reforms.

It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, ...

Opinion: A settlement agreement between and Federal Trade commission and Express Scripts may prove more transformative than any single pricing overhaul because it has restructured the rebate-driven ...

Voluntary MFN commitments by 16 manufacturers reportedly cover ~70% of Medicare drug spending, potentially obviating GUARD/GLOBE finalization while avoiding predictable legal challenges. Lindsay ...

Regulators have scrutinized offshore purchasing units for years due to concerns about transparency and tax avoidance. By moving Ascent back to U.S. soil, the FTC aims to bring over $750 billion in ...

This article examines the PBM-related provisions in the 2026 Consolidated Appropriations Act in the context of other federal and state efforts to regulate PBMs, then offers recommendations on ...

TrumpRx was unveiled this month as part of an effort to foster a more competitive marketplace for prescription drugs.

Lower drug prices offered through direct-to-consumer websites like TrumpRx are failing to reach patients with commercial ...

Drug pricing 2026 forces are reshaping pharmacy economics through Medicare negotiations, FTC actions, and federal pricing models.

More than 128,000 Floridians are living with HIV. The state has the second-highest rate of new HIV diagnoses after Georgia, with approximately 4,500 new diagnoses in 2023, the most recent year for ...

Three Republican state senators intend to introduce legislation that would reform pharmacy benefit managers to “better serve Pennsylvania residents,” a Senate Republican press ...